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SUMMARY 
Chronic pancreatitis is an established risk factor for pancreatic ductal adenocarcinoma (PDAC) 
development. Polymorphisms in the pro-inflammatory cytokine gene interleukin 1β (IL-1β), as well  as  
high IL-1β or low IL-1 receptor antagonist (IL-1RA) serum levels, are associated to worse prognosis in 
PDAC patients.  To characterize the role of IL-1β in pancreatic tumorigenesis, we generated a transgenic 
mouse model bearing KRASG12D  mutation combined to chronic inflammation induced by pancreatic 
overexpression of human IL-1β (KC-IL-1β). We found that IL-1β overexpression induced PDAC onset 
in 6 out of 13 KRASG12D bearing animals (46%), with a median overall survival of 10.5 months, 
compared to only 1 out of 13 mice carrying KRASG12D mutation alone (KC)(7.7% p= 0.02).  
In primary pancreatic KRASG12D organoid cultures, IL-1β exposure increased the number of spheroids 
and induced gene expression changes consistent with epithelial to mesenchymal transition (EMT), as 
shown by increased expression of vimentin, Zeb1, Snail. All these changes were counteracted using a 
recombinant human IL-1receptor antagonist (IL1-RA). Consistently, immuno-histochemical analysis 
confirmed that in KC-IL-1β tumor epithelial cells and metastasis were strongly positive for vimentin.  
The relevance of these findings was confirmed in human PDAC, showing higher IL-1 receptor I (IL1-
RI) and vimentin expression in tumor tissue compared with adjacent normal pancreas.   
Regarding the mechanism involved in EMT activation, IL-1β exposure was found to induce an up-
regulation of ribosome biogenesis rate, with consequent down-regulation of p53 protein expression 
which has been shown to be responsible for EMT changes. 
The finding that IL-1β/IL1-RI inflammatory pathway stimulates acinar cell proliferation and promotes 
EMT provides the rationale for a therapeutic strategy based on IL-1β receptor blockade to counteract 
inflammation-induced pancreatic tumorigenesis 
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1. INFLAMMATION AND CANCER 
 
In 1863 Rudolf Virchow hypothesized the presence of a relationship between inflammation and cancer 
by observing that cancers frequently originate at sites of chronic inflammation, and suggesting that the 
inflammatory milieu may enhance cell proliferation (1, reviewed in 2). The link between inflammatory 
process and cancer is now well established (3,4). Chronic inflammation greatly increases the risk to 
develop cancer in many tissues: indeed the development of about 15% of the global cancers is attributable 
to infectious agents, with inflammation as a major component of these chronic infections (5,6).  
The mechanisms underlying the link between inflammation and cancer can be summarized in two main 
pathways. In the intrinsic pathway, primary genetic alterations of oncogenes and tumor suppressors drive 
cancer onset and determine the expression of inflammation-related programs resulting in pro-
inflammarory circuits supporting cancer development. In the extrinsic pathway chronic inflammation 
drives cancer onset, determining genomic instability, facilitating genetic alterations or directly editing 
the host genome. For example, Helycobacter Pylori infection determines gastric cancer, HPV and HCV 
infections cause cervical and hepatic cancer respectively (reviewed in 7). Inflammatory cytokines, which 
can be produced either by cancer cells or tumor-associated leukocytes, are the main factors involved in 
the molecular pathways linking inflammation to cancer. In particular, three cytokines, IL-1, IL-6, and 
TNF-α have been demonstrated to have a major role in this setting through paracrine or autocrine loops. 
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1.1 INTERLEUKIN 1 (IL-1) 
 
IL-1 includes a family of closely related genes: IL-1α, IL-1β, and IL-1 receptor antagonist (IL1-RA), an 
endogenous inhibitor of IL-1.  IL-1α and IL-1β act on the same receptor, but whereas IL-1β is active in 
its secreted form, IL-1α is mainly active in cellular associated form, being rarely secreted (8). Upon 
binding of IL-1, IL-1 receptor activates multiple downstream signaling pathways including NF-KB, 
which regulates multiple cellular processes involved in inflammation and immunity (7,8). Multiple 
studies indicate an important role of IL-1 in carcinogenesis. IL-1 can augment the metastatic capacity of 
cancer cells by modulating inflammatory pathways (9,10). IL-1β has been demonstrated to increase 
tumor invasiveness, adhesiveness, and angiogenesis in murine models of carcinogen-induced cancers 
(11). IL-1 has been implicated in hepato-carcinogenesis and pancreatic tumorigenesis (12,13). IL-1β  
polymorphisms are associated with increased risk of gastric cancer onset (14). Furthermore gastric 
specific IL-1β expression in IL-1β transgenic mice, leads to chronic gastric inflammation and cancer 
(15). Taken together these data strongly support a role of IL-1 signaling in the pathogenesis of 
gastrointestinal tract cancers. 
 
 
1.2 INTERLEUKIN 6 (IL-6) 
 
Besides NF-KB, JAK/STAT signaling is one of the main pathways activated in inflammation-associated 
tumorigenesis. Importantly these two pathways are tightly interconnected, since STAT3 signaling is 
required for the maintenance of NF-KB activation (16). The main activator of JAK/STAT signaling in 
inflammation is IL-6, which in turn is a NF-KB target gene (17). The NF-KB-IL-6-STAT3 axis, leads to 
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increased transcription of several known oncogenes, such as bcl-2, MCL-1, MYC, Cyclin D, which 
protect from apoptosis and drive proliferation of malignant cells (18). JAK/STAT signaling can be 
involved also in tumor–associated immune suppression, by regulating the expression of cytokines 
affecting the polarization of T-helper subsets, and programmed death ligands (inhibiting the function of 
cytotoxic T cells) (19,20). 
Recently, a new pathway connecting IL-6 and cancer has been described. IL-6 has been shown to up-
regulate ribosome biogenesis thus decreasing the binding of ribosomal proteins to MDM2 with the 
consequent increased MDM2-mediated p53 degradation. The down-regulation of p53 was responsible 
for the activation of the epithelial-mesenchymal-transition program (21).  The pathogenetic role of IL-6 
signaling is well established in several types of cancer, including hepatocellular carcinoma, multiple 
myeloma and lymphoma (22-24).  
 
 
1.3 TUMOR NECROSIS FACTOR α (TNF-α) 
 
Increased expression of the proinflammatory cytokine TNF-α is detected in multiple types of tumors, 
including ovarian, breast, bladder, prostate, colorectal, and lymphoid cancers (reviewed in 7). TNF-α  
regulates angiogenesis and metastasis in solid tumors, and facilitates epithelial to mesenchymal transition 
(25). High levels of circulating TNF-α have been associated with poor prognosis in hematologic 
malignancies of both lymphoid or myeloid origin (26). Importantly, transgenic mice lacking the TNF-α 
gene are resistant to skin carcinogenesis, further supporting a role of TNF-α in the pathogenesis human 
cancer (27). 
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2.  PANCREATIC CANCER 
 
Pancreatic ductal adenocarcinoma (PDAC) will become the second leading cause of cancer deaths in the 
United States by 2030 (28). 
Surgical resection is the most effective treatment, but just few patients are eligible for a radical procedure 
at the time of diagnosis, and even among the resected ones, survival is very poor, with less than 20% of 
patients alive after 5 years. Systemic chemotherapy provides only a modest benefit for advanced disease, 
and cure is still elusive. More reliable early detection methods are needed, as well as increased 
understanding of the mechanisms of metastasis and therapeutic resistance. 
Despite the high biological complexity of PDAC, four genes are recurrently mutated in the majority of 
patients. Mutation in KRAS occurs in more than 90% of cases, and tumor suppressors CDKN2A, p53, 
DPC4/SMAD4 are altered in the 95%, 70% and 55% of patients, respectively (29). 
Point mutations in codon 12 of KRAS gene (KRASG12D or KRASG12V) are the most commonly identified 
in human pancreatic adenocarcinoma (30). This and other mutation that activate KRAS have been found 
in precancerous lesions, like acinar to ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia 
(PanIN), ranging from low-grade PanIN (PanIN-1A/1B) to high grade PanIN (PanIN-2/3) (31).  
Cellular responses to Ras activation vary and depend on the cell type, Ras isoform, expression level and 
wild-type allele status. For example, targeted overexpression of activated K-ras in the pancreas often 
leads to the development of pancreatic acinar hyperplasia or dysplasia, but not invasive cancer. 
Conversely, expression of activated KRASG12D at a physiological level induced by Pdx1-cre is sufficient 
to initiate the development of murine PanIN. The oncogenic function of mutant K-ras protein  
is therefore significantly influenced by the expression level of the mutant KRAS allele or the ratio of the 
wild-type to mutant K-ras protein (32-34).  
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Given the frequency of KRAS mutations in PDAC and their presence in early precursor lesions, ADM 
and PanINs, the activation of oncogenic KRAS has been recognized to be the first event in pancreatic 
carcinogenesis, playing a pivotal role in the ADM-to PanIN-to PDAC progression.  
Nevertheless, since KRAS mutation alone is sporadically sufficient to drive the progression to full-blown 
pancreatic cancer in transgenic mice (35,36) additional oncogenic events must take place in order to 
accelerate pancreatic carcinogenesis. 
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3.  INFLAMMATION AND PANCREATIC CANCER 
 
The potential association between chronic pancreatitis (CP) and pancreatic cancer is matter of debate 
since many years. The risk of PDAC development in patients affected by chronic pancreatitis is difficult 
to assess, due to the difficult diagnosis of the disease itself.   Indeed diagnostic criteria for CP vary from 
center to center, the disease shows often low symptoms and pancreatic biopsy or direct visualization of 
the organ is difficult (37). 
Most of the studies,  case control series or studies relying on data case register, reported relative risk of 
PDAC development patients diagnosed with chronic pancreatitis variable from 2.3 to 18.5 (38,39).  
More recently, a prospective single center study confirmed the association between chronic pancreatitis 
and pancreatic cancer, with a standardized incidence ratio of 26.7 (40).  
However, the mechanisms underlying the risk of pancreatic cancer in CP patients are unclear. Ductal 
epithelial hyperplasia, metaplasia and dysplasia and KRAS mutations have been described in CP patients, 
suggesting an oncogenic multistep sequence. Chronic pancreatic inflammation may account for the 
increased risk of PDAC in the course of CP whether induced by environmental, genetic, or other causes, 
as is the case for other premalignant disease. The duration of CP may influence the magnitude of the 
increase in the risk of pancreatic cancer, as suggested by the estimated cumulative risk of 40% found in 
patients with hereditary pancreatitis. However, only 1.1% of CP patients developed PDAC, and CP may 
account for only 0.1% to 5% of cases of pancreatic cancer compared with an attributable risk of 
approximately 30% for smoking (40). 
Taken together, these evidences show that patients affected by any form of CP have an increased risk of 
developing PDAC: patients with an early onset pancreatitis, like hereditary or tropical pancreatitis have 
rates of pancreatic cancer that are at least 50-fold greater that in the healthy population. However, a 
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policy of pancreatic cancer screening in CP patients does not seems to be justified. Moreover, diagnosing 
PDAC in CP patients remains challenging and more reliable screening tests will need to be developed 
before screening for pancreatic cancer in patients with chronic pancreatitis becomes feasible.  
Moreover, the connection between chronic inflammation and epithelial-to-mesenchymal transition 
(EMT) process has recently been established in pancreatic cancer, starting from early stages of 
tumorigenesis (41).  
Polymorphisms in pro-inflammatory cytokine genes such as IL-1β, TNF-α and IL-6 are known to 
increase the risk of human pancreatic cancer, and high serum levels of IL-1β and IL-6 are associated to 
worse prognosis in advanced PDAC patients (42-45). 
IL-1β is a pleiotropic pro-inflammatory cytokine, produced by monocytes, macrophages, and epithelial 
cells, and it is part of the interleukin-1 family, [which includes IL-1α and IL-1 receptor antagonist (IL1-
RA). IL-1β is involved in many cellular activities, including cell proliferation, differentiation, and 
apoptosis and it plays a crucial role during pathogenesis of pancreatitis in humans and mice (46,47). 
Moreover, high IL-1β or low IL1-RA serum levels are associated with worse survival in human PDAC 
(48). Taken together these evidences confirm that inflammation could play a major role in pancreatic 
tumorigenesis. Nevertheless, the specific role of IL-1β is still poorly defined. 
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4. GENETICALLY ENGINEERED MOUSE MODELS (GEMMs) OF 
PANCREATIC CANCER  
 
Over the past 20 years the adoption of molecular biological techniques for the genetic manipulation of 
the mouse has resulted in a vast surge of interest in using the mouse as a model system for the 
investigation of almost all facets of mammalian biology. Remarkably, it has now become possible to 
genetically alter the mouse genome with nucleotide precision, obtaining genetically engineered mouse 
models (GEMMs). Incorporation of exogenous DNA into the mouse genome to produce a transgenic 
animal can be achieved by pronuclear injection of DNA in the fertilized zygote. Transgenic animals 
produced by this method are generally gain-of-function mutants since the transgene is designed either to 
express a novel gene product or to deregulate a normal gene. When gene targeting (precise alteration of 
endogenous genes) is accomplished by homologous recombination in embryonic stem cells it is possible 
to generate null or knockout mutations. 
More recently, strategies exploiting site-specific DNA recombination have been incorporated into 
transgenic and gene-targeting procedures to allow in vivo manipulation of DNA in embryonic stem cells 
or living animals. A large number of site-specific DNA recombinases have been described from bacteria 
and yeast, and the recombination reactions that they catalyze span a wide range of complexity. The 
relative simplicity and efficiency of Cre recombinase from bacteriophage P1 has made it particularly 
useful for the generation of transgenic mice. Cre recognizes a 34-bp site on the P1 genome called loxP 
and efficiently catalyzes reciprocal conservative DNA recombination between pairs of loxP sites: Cre-
mediated recombination between two directly repeated loxP sites results in excision of the DNA between 
them as a covalently closed circle. To obtain a recombinant activation of gene expression it is 
advantageous to design a dormant transgene that can be activated after establishment of the transgenic 
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line, since often the introduction of a transgene into the mouse results in either morbidity or such reduced 
viability that it is difficult to maintain the transgenic mouse line by breeding. One way of doing this is 
by inserting a lox STOP cassette between the potentially toxic transgene and its promoter. After 
establishment of a transgenic line, the STOP signal can be removed by Cre-mediated excision, by 
intercrossing with a second mouse expressing Cre, to activate the transgene as desired. 
The tissue specificity of expression  for the recombinant activated dormant transgene is a function both 
of the promoter specificity of the target transgene and of the promoter specificity of the Cre transgene. 
Moreover, the spatial and temporal occurrence of recombination can be completely specified by placing 
Cre under the control of a promoter having the desired spatial and temporal pattern of expression.  
A variety of genetically engineered mouse models of pancreatic cancer have been developed over the 
last decade using the Cre/lox System.  
Hingorani and colleagues (35) developed a mouse model of PanIN lesions, Pdx-1cre;LSL-KRASG12D 
(KC), targeting the expression of KRASG12D  to pancreatic progenitor cells, through the construction of a 
conditionally expressed allele (35). The targeting vector contained Lox-STOP-Lox (LSL) construct 
inserted into the mouse genomic KRAS locus upstream of a modified exon 1 engineered to contain a G 
to A transition in codon 12. This mutation results in a glycine to aspartic acid substitution in the expressed 
protein, compromising both the intrinsic and extrinsic GTPase activities and resulting in constitutive 
downstream signaling activation of Ras effector pathways. The expression of the mutated allele is 
achieved by interbreeding LSL- KRASG12D mice with animals that express Cre recombinase from the 
pancreatic-specific promoters PDX-1, a pancreatic progenitor marker expressed since E8.5, and its 
homozygous deletion is an embryonic lethal event (49). In the same way, Hingorani and colleagues (50) 
developed a metastatic cancer mouse model, targeting the expression of both KRASG12D   and Trp53R172H 
Pdx1-cre;LSL- KRASG12D; LSL- Trp53R172H (KPC), an ortholog of one of the most common TP53 
mutation in human PDAC, to progenitor cells of the mouse pancreas (50).  
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In conclusion, one of the principle advantages of GEMMs is the stepwise evolution of a nascent tumor 
from normal precursors that results in a more authentic tissue architecture compared to xenografts that 
are reconstituted from cell lines, or are lacking in immune cells. Thus, the innate complexities of GEMMs 
make them ideal tools to study mechanisms of tumorigenesis and test the efficacy of cancer therapies, 
playing an increasingly prominent role in identifying the relevant patient population most likely to benefit 
from any given treatment (51,52). 
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5.  AIMS 
 
The aim of the present study was to investigate the role of chronic inflammation induced by IL-1β  in 
PDAC development.  For this purpose, we generated a novel transgenic mouse model characterized by 
KRASG12D mutation combined to a pancreatic overexpression of human IL-1β (KC- IL-1β).  We followed 
longitudinally a cohort of  KC-IL-1β mice up to 20 months of age for evidence of disease progression. 
Moreover, we studied the effect of IL-1β  on primary epithelial pancreatic cells from KRASG12D mice by 
evaluating  the very first step of carcinogenesis, as identified in ADM process. We found that IL-1β-
induced chronic pancreatitis accelerated pancreatic carcinogenesis in KRASG12D mice and stimulated 
ADM and promoted EMT in organoid cultures from pancreas of KRASG12D mice through IL-1β/IL1-RI 
pathway. The latter changes were counteracted by treatment with a human recombinant IL-1 receptor 
antagonist, able to competitively block the IL1-RI receptor.  We also investigated the mechanism 
underlying EMT induction following IL-1β stimulation. 
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6. RESULTS 
 
6.1 Generation of KC-IL-1β mice: functional and histo-pathological characterization   
To generate the new KC-IL-1β murine model we took advantage of the constitutive model of chronic 
pancreatitis, Elastase sshIL-1β mice line 124 (47) inter-breeded to LSL-KRASG12D mice (53).  Double 
positive animals Elastase sshIL-1β; LSL-KRASG12D were further crossed to homozygous PDX-1-Cre 
mice, to ensure the excision of the silencing cassette at the LoxP sites and the subsequent expression of 
mutant allele KRASG12D in pancreatic progenitor cells, starting from embryonic day 8 in fetal mouse 
(49). Thus, we obtained mutant PDX-1-Cre;LSL-KRASG12D;Elastase sshIL-1β animals (KC-IL-1β), 
characterized by mutant KRASG12D expressed under the PDX-1 promoter (35) and human IL-1β 
expression driven by rat elastase promoter (Figure 1A). 
To confirm the functional activity of KC-IL-1β, we performed enzyme-linked immunosorbent assay 
(ELISA) in murine pancreatic protein extracts, validating the increased secretion of hIL-1β in KC- IL-
1β mice at 7 weeks of age (Figure 1B). 
Figure 1.  
 
 
 
 
 
 
Figure 1. A) Genetic design of KC-IL-1β transgenic mice. B) ELISA from KC-IL-1β pancreatic tissues 
confirming increased IL-1β protein expression compared with wild type mice. 
B A 
W T K C - I L -1 
0
1 0
2 0
3 0
I
n
te
r
le
u
k
in
-1

 (
p
g
/m
g
 p
r
o
t)
*
16 
 
Histologically, KC-IL-1β mice displayed features of mild chronic inflammation, periductal fibrosis, 
acinar atrophy, ADM and PanIN1A-1B lesions since 8 weeks of age (Figure 2A: panel A,D,G). These 
changes progressed in severe chronic pancreatitis, with increased stromal reaction and loss of regular 
pancreatic parenchyma, replaced completely by dysplastic lesions in mice of 20 weeks of age and older 
(Figure 2A: panel B). At the same age, 75% of KC-IL-1β mice showed PanIN3 lesions and 25% invasive 
PDAC (Figure 2A: panel J,K). None of the age-matched control mice, Elastase hIL-1β and KC mice, 
developed pancreatic invasive lesions (Figure 2A: panel A-F).  
One-year old KC-IL-1β mice developed malignant lesions: tumors were histologically characterized and 
covered a broad histopathological aspect, ranging from mucinous cystic type to carcino-sarcoma-like 
features (Figure 2A, panel I). Instead, one-year  old Elastase hIL-1β and KC mice showed respectively 
severe pancreatic atrophy with adipose substitution, tubular complex and ADM the first, and diffuse 
PanIN 1-2 lesions the latter, both without a clear malignant evolution (Figure 2A: panel C,F). These data 
confirmed that IL1β overexpression cooperates with KRAS mutations accelerating the progression of 
precursor lesions and the PDAC development in KC- IL-1β. 
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Figure 2 
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Figure 2. A) Histological sections from Elastase-IL-1β (panel A-C), KC (panel D-F) and KC-IL-1β 
(panel G-I). B) Number of PanIN-3 lesions and PDAC in  KC-IL-1β mice and controls mice at 20 weeks 
of age. 
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6.2  IL-1β pancreatic overexpression accelerates the development of pancreatic invasive 
tumors in KRASG12D mice 
 We followed longitudinally a cohort of 13 KC-IL-1β mice up to 20 months of age for evidence of disease 
progression. 46% of animals (6/13) developed invasive pancreatic tumors, with a global median overall 
survival of 10.5 months. As internal controls, we bred both Elastase hIL-1β and KC mice. As previously 
published, the chronic pancreatitis model never developed invasive PDAC, rather a progressive acinar 
atrophy and pancreatic adipose substitution (Figure 2A: panel A-C) and none of the Elastase hIL-1β mice 
died during the period of observation. Differently, one mouse of the KC cohort developed PDAC and 
succumbed  to cancer (1/13 – 7.7%) at 14 months of age. When directly compared, IL-1β overexpression 
mouse model significantly increased the rate of PDAC development in KRASG12D animals (Chi Square 
0.02) (Figure 3A, 3B)  
PDX-1-Cre;LSL-KRASG12D;LSL-Trp53R172H mice (KPC) were followed as well as positive control of 
carcinogenesis, showing PDAC incidence (15/15) and global overall survival (5.4 months) consistent 
with published data (Figure 3A). 
Figure 3 
 
Figure 3. A) Overall survival (Kaplan-Meier) curve of Elastase IL-1β, KC, KC-IL-1β, KPC mice. B) 
Contingency graph indicating a significant increase in KC-IL-1β tumor incidence in comparison to KC. 
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All the tumors were histologically confirmed and KC-IL-1β neoplastic features are summarized in 
Table1.  
 
Liver metastasis were found in 50% of animals (3/6) whereas abdominal ascites in 33% of animals (2/6). 
Histologically, primary tumors were poorly differentiated PDAC, with malignant gland and infiltrating 
single cells, characterized by marked nuclear polymorfism and increased nuclear/cytoplasmatic ratio, 
and surrounded by a prominent periductal stromal reaction of spindle-like cells (Figure 4). One case 
showed features of mucinous-cystic-like neoplasm with low grade of cytological atypia, but 
characterized by cribriform architecture complexes and extensive malignant mucinous metaplasia with 
invasive capability. 
Figure 4 
 
Figure 4. A) Macroscopic morphological pattern of liver metastasis and primary tumors  KC-IL-1β (A-
C). Histological sections from metastatic (D) and primary tumors (E,F). 
ID Age (mo) Sex PDAC Histology Liver Lung Ascites PW/BW
D-1147 8.1 male yes invasive PanIn3 metastasis no no 1.01/28
E-2169 5.5 male yes adenocarcinoma no no yes 2.05/35
D-7249 9.9 male yes anaplastic carcinoma no no no 0.85/35
D-7247 13 male yes mucinous cystic neoplasm metastasis no no 2.0/35
E-9054 10.8 male yes invasive PanIn3 metastasis no yes 2.01/35
D-7244 16.2 male yes adenocarcinoma no no no 1.01/29
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6.3 IL-1β pancreatic overexpression increases proliferation in KRASG12D mice and 
stimulates ADM in organoid cultures through IL-1β/IL1-RI pathway 
To better understand the early steps of carcinogenesis in KC-IL-1β mice, we analyzed the proliferative 
activity in paraffin-embeeded pancreatic sections in 20 weeks old Elastase hIL-1β, KC and KC-IL-1β 
mice. Consistently with the overall survival trend, the proliferation index evaluated by Ki67 
immunostaining was significantly higher in KC- IL-1β samples in comparison to age-matched control 
mice. In particular the majority of Ki67 expressing cells were found in pancreatic epithelial structures 
like ADM and PanINs lesions, suggesting a major effect of IL-1β-promoted pancreatitis on the pancreatic 
epithelial compartment (Figure 5: panel A,B). 
Figure 5 
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Figure 5. Ki-67 staining of samples from wild type pancreas (panel A), Elastase hIL-1β (panel B), KC 
(panel C) and KC-IL-1β (panel D). Quantitative evaluation of Ki-67 label index (panel E). 
 
Thus, to test if IL-1β overexpression plays a role directly on epithelial cells or if its effect is mostly 
mediated by immune cells involved in inflammation, we studied IL-1β effect on primary epithelial 
pancreatic cells in the very first step of carcinogenesis, as identified in ADM process (54,55).   
To study ADM we took advantage of 3D pancreatic organoid cultures, able to reproduce a regenerative 
and dedifferentiation program in vitro (56,57).  
We isolated KRASG12D epithelial cells from KC pancreata and we treated them as shown in Figure 6A. 
IL-1β exposure promoted the ADM process, as shown by the increased number of KRASG12D organoids 
in comparison to the untreated KRASG12D  spheroids (Figure 6B-C).  Then, to rule out unspecific effect 
of IL-1β administration in increasing organoid number, we treated cells with a human recombinant IL-1 
receptor antagonist, able to competitively block the IL1-RI receptor. Thirty-minutes of RA pre-treatment, 
followed by 24 hours IL-1β administration, counteracted the cytokine effect on organoid number (Figure 
6C), suggesting that its effect is primarily directed on epithelial cells and it is specifically mediated by 
IL-1RI. 
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No differences in organoids number were found between untreated KRASG12D   and KRASG12D  spheroids 
exposed to IL1-RA alone, proving that IL1-RA exposure itself has no toxic effects on primary pancreatic 
cells (Figure 6B-C). 
Taken together, these data show that IL-1β acts directly on epithelial KRASG12D cells increasing 
proliferation in vivo and inducing ADM process in pancreatic organoid cultures. This effect is mediated 
by IL1-RI on pancreatic cells, and it can be blocked using the human IL1-RA (anakinra), currently 
approved  by FDA for rheumatoid arthritis treatment. 
Figure 6 
 
 
 
Figure 6. A) Schematic representation of IL-1β treatment B) Images of spheroid cultures C) Quantitative 
evaluation of the number of spheroids in untreated and IL- 1β and RA treated spheres. 
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6.4 IL-1β pancreatic overexpression promotes EMT activation in KC-IL-1β mice 
Since inflammation is shown to be a promoter of EMT in many solid tumors (58) we looked at the role 
of chronic pancreatitis  on EMT process during carcinogenesis in KC-IL-1β mice. Starting from 8 weeks 
and up to 20 weeks of age, we appreciated a progressive decrease of the number of cells stained by anti 
E-cadherin antibody in pancreatic tissue (Figure 7: panel A,B), up to a very low staining in cancer lesion 
(Figure 7: panel C). The opposite trend is observed after vimentin staining, showing a constantly increase 
of vimentin positive staining in epithelial cells (Figure 7: panel D-F). Notably, at 20 weeks of age and in 
full-blown pancreatic cancer not only the stromal microenvironment reacted to vimentin staining, but 
also single ductal cells were vimentin positive in PanIN lesions and in the tumor epithelial component. 
These data let us to speculate about a mesenchymal transformation of epithelial pancreatic cells in early 
pre-neoplastic stage, due to an early and chronic IL-1β exposure in pancreatic tissue.  
Taken together, these data suggest that IL-1β overexpression stimulates the loss of epithelial 
characteristics in pancreatic cells, transforming acinar and ductal cells in fibroblast-like cells, potentially 
not distinguishable from the surrounding stroma during PDAC development.  
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Figure 7 
 
 
Figure 7. A-C) E-Cadherin staining on pancreatic sections from KC-IL-1β mice 8 weeks old (A), 20 
weeks old (B) and KC-IL-1β mice affected by PDAC (C). D-F) Vimentin staining on pancreatic sections 
from KC-IL-1β mice 8 weeks old (C), 20 weeks old (D) and KC-IL-1β mice affected by PDAC (F).  
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6.5 IL-1β exposure promotes EMT in KRASG12D pancreatic organoid cultures through 
IL-1β/IL1-RI pathway 
To better understand how IL-1β induces EMT in early steps of carcinogenesis, we studied the effect of 
IL1β exposure on primary KRASG12D  organoids (see treatment protocol in figure 8A).  
Vimentin expression was highly increased in spheroids culture after IL-1β exposure when compared to 
untreated organoids (Figure 8B, 8C: panel A-D). Pre-treatment with IL1-RA counteracted the IL-1β 
effect, suggesting that the EMT process induced by IL-1β, as well as its pro-proliferative effect, are 
mediated by IL-1R in primary KRASG12D  organoids (Figure 8B, 8C: panel E-F). 
Thus, we analyzed two important transcription factors able to mediate EMT in pancreas, Zeb1 and Snail: 
we showed that both of these markers greatly increased after IL-1β exposure. This effect, as well as 
vimentin expression, was antagonized by IL-1RA pre-treatment on KRASG12D  organoids  (Figure 8D, 
8E), confirming the relevance of IL-1β/IL1-RI pathway in EMT induction in pancreatic organoids.  
Interestingly, beside IL-1β effect on proliferation and EMT, we observed the increase of  inducible Nitric 
Oxide Synthase (iNOS) on KRASG12D  organoids after IL-1β treatment. iNOS gene activation induces 
NO production, a reactive oxygen species involved in immune response and angiogenesis in many cell 
types. Again, the effect of IL-1β on iNOS expression level was blocked by IL-1RA administration, 
proving that IL-1β plays a direct role on in oxidative stress induction, and this action is mediated by IL1-
RI activation (Figure 8F).  
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. A) Schematic representation of IL-1β treatment. B) Vimentin mRNA expression level after IL-
1β treatment, combination treatment of IL-1β and IL1-RA (IL-1 β + RA) and IL1-RA alone (RA). C) H&E 
sections (panel A-C) and Vimentin staining (panel D-F) of spheroids cultures: untreated spheres (panel 
A,D), IL-1β treated spheres (panel B,E), and combination treatment of IL-1β and IL1-RA (panel C,F). 
D) Zeb1 mRNA expression level after IL-1β, combination treatment IL-1 β + RA and RA treatments. E) 
Snail mRNA expression level after IL-1β, IL-1 β + RA and RA treatments. F) Zeb1 mRNA expression 
level after IL-1β, IL-1 β + RA and RA treatments. 
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Moreover, the crucial role of IL1-RI has been confirmed further in human PDAC samples, showing a 
higher gene expression level of the IL-1 receptor in tumor tissue, in comparison to the level found  in the 
adjacent normal pancreatic areas (Figure 9A). Moreover we detected a strong IL1-RI and vimentin 
reactivity in human PDAC samples (Figure 9B: panel A-C). Notably, vimentin expression was found in 
both epithelial and stromal compartment in PDAC (Figure 9B: panel B). 
This suggests a strict connection between IL1-RI signaling and EMT process. In particular the high 
expression of IL1-RI and the strong vimentin reaction, let us speculate that IL-1β/IL1-RI inflammatory 
pathway can promote EMT and dissemination in human pancreatic tissue, providing the rationale for a 
therapeutic strategy based on  IL-1β receptor blockade in individuals at high risk for pancreatic cancer 
or affected by chronic pancreatitis. 
Figure 9.  
 
 
 
 
 
 
 
Figure 9. A) IL-1R mRNA expression level in normal and tumor human pancreatic tissues. B) H&E 
(panel A), vimentin (panel B) and  IL-1R (panel C) staining on human PDAC samples. 
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6.6 IL-1β exposure up-regulates the ribosome biogenesis rate and down-regulates the 
expression of p53 
The above reported results indicated that IL-1β was responsible for the induction of EMT both in the 
pancreas of KC-IL-1β mice and in pancreatic organoid cultures.  
There is evidence that IL-6, one of the major interleukin involved in the relationship between 
inflammation and cancer, induces the acquisition of cellular phenotypic changes characteristic of EMT, 
in human cancerous and non-cancerous cell lines and in human colon epithelial cells in ulcerative colitis. 
These EMT changes are due to the fact that IL-6 enhances rRNA transcription which, by reducing the 
availability of ribosome proteins for MDM2 binding, increases the MDM2-mediated proteasomal 
degradation of p53, through the well- established ribosomal proteins/MDM2/p53 pathway (59,60). 
Therefore, we wondered whether the mechanism described for IL-6 induction of EMT might be valid 
also for IL-1β. For this purpose we analyzed the effect of IL-1β on ribosome biogenesis  on KRASG12D  
organoids. The changes in rRNA transcriptional activity in these cell exposed to IL-1β were ascertained 
by using real-time PCR analysis of the 45S pre-rRNA expression. This analysis revealed that IL-1β 
greatly enhanced rRNA transcription (Fig. 10A). Then, we evaluated the effect of IL-1β exposure on p53 
protein expression in primary KRASG12D cells by Western blot analysis. After IL-1β treatment the 
amount of p53 appeared to be markedly reduced in comparison not only with control cells but also with 
cells exposed to IL-6 (Fig. 10B). 
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Figure 10 
 
Figure 10. A) 45S pre-rRNA mRNA levels in untreated and IL-1β exposed (24 hours)  KRASG12D spheres. 
B)Western Blot evaluation of p53 level in untreated, IL-1β and IL-6 exposed (24 hours) primary 
KRASG12D cells.  
 
Therefore, these results indicated that IL-1β activated the same pathway that in IL-6 treated cells was 
responsible for activation of the EMT process. Since the enhancement of ribosome biogenesis was at the 
basis of EMT activation, we evaluated whether this metabolic change also occurred in the pancreas of 
Elastase hIL-1β mice and other mouse models of chronic pancreatitis (wild type mice treated with 
cerulein) and in KC-IL-1β and KPC mice. For this purpose we measured the size of nucleoli of acinar 
cells in histological sections stained with the silver procedure specific for nucleolar proteins on the 
nucleolar organizer, the AgNOR proteins (61). Since the distribution of the AgNOR proteins within the 
cell is directly proportional to the nucleolar size and to its ribosome biogenesis rate, their quantitative 
morphometric analysis allows precise information to be obtained on the rate of rRNA transcription of 
tissues in situ (61,62). As shown in Fig. 11A pancreatic acinar cells from Elastase hIL-1β mice, as well 
as KC-IL-1β, exhibited an increased amount of the silver-stained nucleolar structures which indicated an 
up-regulated ribosomal biogenesis rate  in comparison with the corresponding cells from wild-type mice. 
Taken together, these observations may lead to conclude that factors produced in the inflammatory 
milieu, such as IL-6 and IL-1β, increase the ribosome biogenesis, the first step which activates the EMT 
process. For this reason, we also investigated whether an up-regulation of rRNA synthesis actually occurs 
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in human pancreatic acinar cells during chronic pancreatitis (Figure 11B). Quantitative morphometric 
analysis of the size of nucleoli in five cases of chronic pancreatitis  carried out on histological section 
selectively silver-stained for AgNOR proteins, clearly showed that the amount of the nucleolar silver-
stained structures of acinar cells from chronically inflamed pancreas was statistically higher than that of 
acinar cells from normal pancreas (5.23 µm ± 1.78 SD vs  3.47 µm ± 1.14 SD; p<0.01). 
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Figure 11 
Figure 11. A) AgNORs staining and quantitative evaluation in pancreatic samples from wild type (WT) 
(panel A), Elastase hIL-1β (panel B), wild type mice 3 days (panel C) and 7 days (panel D) after  
cerulean treatment, KC-IL-1β (panel E) and KPC mice (panel F) B) AgNORs staining of human normal 
pancreatic samples and chronic pancreatitis (panel A-B) 
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7. DISCUSSION 
 
Many studies have proved that inflammation is a risk factor of pancreatic cancer onset. However the 
exact mechanism linking chronic pancreatitis and PDAC development has not been completely defined 
yet.  
Here, we reported a new mouse model of pancreatic cancer arisen from chronic pancreatitis, 
characterized by a tumor incidence of more than 40%, created by combining pancreatic IL-1β 
overexpression and KRASG12D mutation in  PDX-1-Cre;LSL-KRASG12D;Elastase sshIL-1β mice. These 
animals showed an increase in pre-neoplastic epithelial cells proliferation, a faster development of 
PanINs and faster progression to invasive PDAC in comparison to KC model.  
There is evidence that IL-1β level is elevated in many human cancers (8). IL-1β is mainly released by 
tumor-associated macrophages in the tumor microenvironment, where it can act promoting angiogenesis, 
tumor growth and metastasis (63). Moreover, the enforced expression of IL-1β is strictly correlated with 
tumor progression and advanced metastatic disease in cancer patients (64,65). 
In this study we highlighted two critical events due to high IL-1β expression. First, we demonstrated the 
role of IL-1β on epithelial pancreatic  cell malignant transformation, and second, we showed that IL-1β 
acts as EMT trigger, essential for cancer cell dissemination and metastatic spread. Both these crucial 
aspects, needed for survival and dissemination of PDAC, were blocked by antagonizing the IL1 receptor.   
Moreover, using a pure epithelial organoid pancreatic culture, we demonstrated that IL-1β stimulates 
directly the ADM process, thus proving the specific effect of IL-1β on PDAC initiation and identifying 
this cytokine as a crucial element, among all the tumor microenvironment elements, that was able to 
mediate inflammation in cancer initiation. In the same kind of culture we showed the direct role of IL-
1β on pancreatic EMT, proved by the increased expression of Vimentin,  Zeb1 and Snail, and restored 
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by IL1-RA treatment, to antagonize IL-1β effect. The EMT process induced by IL-1β was very likely the 
consequence of the down-regulation of p53 expression. In fact, IL-1β exposure greatly stimulated the 
rRNA transcription, which has been shown to increase the MDM2-mediated degradation of p53 (21,66), 
and p53, as it has been repeatedly demonstrated, negatively controls the activation of the EMT program 
(21, 67-69) 
Another important effect of IL-1β stimulation we observed in the present study was the very high increase 
in iNOS gene expression in KRASG12D pancreatic organoids. iNOS, the synthase isoform most commonly 
associated with malignant disease, is known to be responsible for the induction of the production of  high 
level of NO, which in turn stimulates malignant transformation, angiogenesis, and metastasis spread (65). 
Thus, our observation suggests that IL-1β may play a key role also in the oxidative stress induction, with 
an inflammation-mediated production of NO.  Moreover, since its known from literature that IL-1β pro-
tumorigenic activity is mediated by NF-κB (70), and iNOS gene promoter is regulated by NF-κB 
dependent activation, we can argue about an IL-1β mediated stimulation of this transcript, highlighting 
its direct effect on oxidative stress induction.   
In this study, every effect induced by IL-1β stimulation has been counteracted by using the human 
recombinant IL1-RA, highlighting a therapeutic strategy in blocking IL-1β pathway during 
tumorigenesis, as recently showed in pancreatic cancer cells and orthotopic nude mice (71).  
Moreover, the IL1-RA anakinra is an FDA approved compound for severe rheumatoid arthritis treatment 
(72) and its use in combination with chemotherapy is currently underway in phase I trials for advanced 
breast and pancreatic cancer patients (clinicaltrials.gov/ ct2/show/ record/ NCT02021422; 
clinicaltrials.gov/ ct2/ show/record NCT02021422). 
In conclusion, the crucial role of IL-1β we have shown here during PDAC tumorigenesis and progression, 
highlight the importance  to develop  new therapeutic drugs blocking the IL1 receptor signaling, 
especially for those patients affected by chronic inflammation whit high IL-1β level, in order to block 
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the cytokine action since the very first steps of carcinogenesis, where its inhibition may be of crucial 
effect in blocking disease progression towards metastatic PDAC.  
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8. MATERIALS AND METHODS 
 
Pancreatic Tissue Preparation:  
Pancreata were isolated and washed in cold DEPC water. Portions were cut and snap frozen in liquid 
nitrogen for protein and RNA extraction. Proteins were extracted using a tissue homogenizer and RIPA 
buffer + protein inhibitors (complete EDTA free, Roche Applied Science, Indianapolis, IN, USA) and 
protein quantification was performed using the Bradford method. For RNA isolation, frozen samples 
were ground using a pestle in liquid nitrogen and homogenized in Trizol reagent (Invitrogen, Carlsbad, 
CA, USA). RNA was extracted according to manufacturer’s instructions and cleaned using RNeasy 
columns (Qiagen, Valencia, CA, USA). The remaining tissue was fixed overnight in 10% neutral 
buffered formalin before transfer to 70% ethanol. Specimens were then processed and embedded in 
paraffin for histologic analysis. 
 
Interleukin IL-1β Quantification:  
To quantify human interleukin-1β in pancreatic tissue, ELISA assays were performed with the 
Quantikine® Human IL-1β immunoassay (R&D systems, Minneapolis, MN, USA, #DLB50) according 
to the manufacturer’s instructions.  
 
Histology,  immuno-histochemistry,  immunofluorescence  and  microscopy:  
5μm  paraffin embedded   were   prepared   for   immunohistochemistry   For  immunohistochemical  
staining. Slides  were deparaffinized  in  xylene  and  endogenous  peroxidase  was blocked  by  incubation  
with  3% hydrogen  peroxide  in  methanol  for  visualization  using  the  peroxidase  reaction. Antigen  
retrieval  was  performed  by  boiling  the  slides  in  citrate  buffer S2 (10mM pH 6.0) in a water bath 
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for 20 min. Slides were rinsed in PBS Tween 0.05% and blocked for  30  min.  with  2%  BSA.  Primary  
antibodies  and  biotinylated  secondary  antibodies  (Jackson Immunoresearch) were diluted in 2% BSA 
and incubated overnight at 4°C. Subsequently, slides were  incubated  with  alkaline  phosphatase  or  
peroxidase  conjugated  streptavidin  (Dako)  and either  VectorRed  substrate  (Vector  Laboratories)  or  
3,3’-diaminobenzidine  (Sigma-Aldrich)  as chromogens, respectively. Slides were counterstained with 
hematoxylin and mounted for viewing. Bright  field  and  fluorescence  images  were  acquired  using  an 
Eclipse  TU2000-U  microscope (Nikon)  connected  to  a  cooled  color  CCD  camera  (RTKE  
Diagnostic  Instruments)  using  SPOT software (Spotimaging) 
 
Quantification  of  immunohistochemical  staining: 
Ki67  positive  cells were  quantified  in  five  high  power  fields  from  at  least  3  mice  per  group.  
 
RNA extraction and quantitative RT-PCR analysis:  
RNA  was extracted from each group using RNAqueous®-Micro Total RNA Isolation Kit (Thermo 
Sci,catalog no.  AM1931).  High-fidelity  cDNA  was  generated from each  RNA  sample  with  the  
Superscript  III cDNA amplification system (Invitrogen). Quantitative RT-PCR reaction samples were 
prepared as a  mixture  with  Quantitect  SYBR  Green  PCR  kit  (Qiagen).  Reactions  were  performed  
using  an Applied Biosystems Prism 9700 PCR machine.  
 
Sphere  Cultures: 
3D  cultures  were  performed  as  described  previously  (Wescott et  al.,  2009), after isolation of primary 
pancreatic epithelial cells from KC mice. Organoids  were  cultured  for  5-7  days  before  analysis.  
Sphere number and size were  analyzed  using  ImageJ  software.   Human IL-1β 50 ng/mL and human 
recombinant  IL1-RA 50 ng/mL containing medium was changed every other day.    
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Western Blotting: 
Protein  extraction  was  performed  on  ice  using  RIPA  buffer with  protease inhibitor  (Complete)  
(Roche)  cocktail  and  phosphatase  inhibitor  (phosSTOP)  (Roche).  Protein samples were subsequently 
separated in 10%Bis-Tris Gel NuPAGE® electrophoresis using MES SDS  Running  Buffer  (Invitrogen, 
CA,  USA).  After  transfer  to nitrocellulose,  membranes  were blocked with 5% BSA, and samples 
were probed with anti p53 primary antibody (Cell Signaling) followed by  horseradish peroxidase-
coupled  secondary antibody.  Images  were  acquired  using  X-ray  film development,  and  bands  were  
antified  with ImageJ. 
 
NOR Silver Staining 
NOR silver staining was performed according to the guidelines of the “International Committee on 
AgNOR Quantitation” (73). In short, slides were moved from water to heat-resistant plastic Coplin jars, 
fully immersed in 10 mM sodium citrate buffer (pH 6.0) and autoclaved at 120C for 20 min. After cooling 
to room temperature in the sodium citrate buffer, slides were stained with silver for 13 min at 37C in the 
dark using a solution of one volume 2% gelatin in 1% aqueous formic acid and two volumes of 50% 
silver nitrate. Sections were finally dehydrated and mounted in Canada balsam without any 
counterstaining.  
Image Cytometry 
Quantitative evaluation of silver-stained nucleolar structures was carried out by image cytometry. 
Morphometric analysis of silver-stained NORs was carried out using the Image-Pro Plus program (Media 
Cybernetics, Silver Spring, MD). The main stages of image processing were as follows: a field was 
selected by the operator at the microscope under a ×40 objective lens. The selected image was then 
captured and stored in the digital memory and displayed on the color monitor. Here the operator 
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interactively defined the gray threshold that permitted automatic quantification of only the black dots 
corresponding to the silver- stained nucleoli. The morphometric analysis was then performed on a cell-
to-cell basis by converging the window over the corresponding nucleus. For each case, the AgNOR area 
of at least 100 nuclei was measured and the mean AgNOR area (±SD) calculated.  
 
Tissue samples: 
Human pancreatitis and pancreatic cancer samples were provided by Dr. Helen Remotti  (Dept.  of  
Pathology – CUMC). Murine  pancreatic  cancer  samples  were  provided  by  Dr. Helen  Remotti,  Dr.  
Gloria  Su  and  Dr.  Ken  Olive.  All  samples  were  anonymized. 
 
Statistical Analysis 
Statistical  testing  and  was  done  using  GraphPad  Prism  software  with  the appropriate  test  for  each  
experiment.  For  experiments  with  two  experimental  groups  two-tailed, unpaired  t-test  were  applied.  
Proportions  were  compared  with  the  test  for  proportions  (Tarca  et al.,  2009). For  experiments  
with  three  or  more  groups,  we  applied  1way  ANOVA  testing  with Bonferroni's  Multiple  
Comparison  Test.  Statistical significance  was  depicted  as  follows: 
*=  p <0.05, **= p <0.005 and ***= p <0.000 
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